Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

735.20 +0.39 (+0.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

66 67 Next >

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

February 02, 2026

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated...

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock? ↗

February 02, 2026

Via Stocktwits

This $24 Million Buy Amid a 45% Stock Drop Signals Conviction in a High-Margin Data Business ↗

January 30, 2026

FactSet delivers integrated financial data and analytics to institutional clients, supporting investment decisions worldwide.

Via The Motley Fool

Regeneron Pharmaceuticals (NASDAQ:REGN) Reports Q4 2025 Earnings Beat Amid Product Transition ↗

January 30, 2026

Via Chartmill

Topics Earnings

Regeneron (REGN) Q4 2025 Earnings Call Transcript ↗

January 30, 2026

Regeneron (REGN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

These S&P500 stocks that are showing activity before the opening bell on Friday. ↗

January 30, 2026

Via Chartmill

Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗

January 30, 2026

Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.

Via Stocktwits

Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025

January 30, 2026

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 2.5% year on year to $3.88 billion. Its non-GAAP profit of $11.44 per share was...

Via StockStory

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

January 30, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow

January 28, 2026

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

2 Healthcare Stocks Poised for a Comeback in 2026 ↗

January 22, 2026

Don't wait too long to press the buy button on these comeback stories.

Via The Motley Fool

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

January 20, 2026

In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion....

Via MarketMinute

Topics Intellectual Property

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

3 Profitable Stocks We Think Twice About

January 18, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

1 Mooning Stock with Exciting Potential and 2 Facing Headwinds

January 12, 2026

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

Topics Economy Energy

Regeneron Just Moved From Underperform To Buy - Here's Why ↗

January 07, 2026

Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment?

Via Benzinga

These S&P500 stocks are moving in today's session ↗

January 07, 2026

Via Chartmill

Why Regeneron (REGN) Stock Is Trading Up Today

January 07, 2026

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the morning session after Bank of America Securities upgraded its rating on the company's stock from 'Underperform' to 'Buy' and...

Via StockStory

Topics Artificial Intelligence

Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

January 02, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

3 Reasons to Avoid REGN and 1 Stock to Buy Instead

December 30, 2025

What a fantastic six months it’s been for Regeneron. Shares of the company have skyrocketed 47.6%, hitting $774.98. This was partly due to its solid quarterly results, and the performance may have...

Via StockStory

Discover which S&P500 stocks are making waves on Tuesday. ↗

December 30, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

3 Cash-Heavy Stocks We Approach with Caution

December 28, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

December 25, 2025

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...

Via PredictStreet

Topics Artificial Intelligence Economy Intellectual Property

The Atomic Architect: How University of Washington’s Generative AI Just Rewrote the Rules of Medicine

December 24, 2025

In a milestone that many scientists once considered a "pipe dream" for the next decade, researchers at the University of Washington’s (UW) Institute for Protein Design (IPD) announced in late 2025 the...

Via TokenRing AI

Topics Artificial Intelligence

Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine

December 24, 2025

As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the...

Via PredictStreet

Topics Artificial Intelligence Economy Intellectual Property

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

December 23, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

December 22, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

Via Stocktwits

Topics Economy Government

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.